Aziz Mottiwala - Jun 8, 2023 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role: Chief Commercial Officer
Signature: /s/ Jeffrey Farrow, Attorney-in-Fact
Stock symbol: TARS
Transactions as of: Jun 8, 2023
Transactions value $: -$2,000
Form type: 4
Date filed: 6/12/2023, 05:25 PM
Previous filing: Jun 8, 2023
Next filing: Jul 21, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TARS	Common Stock	Sale	-$2K	-100	-0.21%	$20.00	48.1K	Jun 8, 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2022.